Healthcare › Drug Manufacturers
Pfizer
- Ticker
- PFE
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers
Price data arrives in a later stage, so no price is shown yet.
Latest news
ImportantPFE
Explain this story: Uthmeier alleges Pfizer misled Florida about its COVID vaccine’s safety
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc., accusing the company of unfair and deceptive marketing regarding its COVID-19 vaccine. The suit, which also names CEO Albert Bourla, seeks monetary damages and an injunction, alleging Pfizer misled consumers and suppressed dissent while being aware of undisclosed safety risks. Pfizer denies the allegations, stating its vaccine representations were accurate and science-based, and that the vaccine has a favorable safety profile and has saved countless lives.
OtherFlorida PhoenixSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc., accusing the company of unfair and deceptive marketing regarding its COVID-19 vaccine. The suit, which also names CEO Albert Bourla, seeks monetary damages and an injunction, alleging Pfizer misled consumers and suppressed dissent while being aware of undisclosed safety risks. Pfizer denies the allegations, stating its vaccine representations were accurate and science-based, and that the vaccine has a favorable safety profile and has saved countless lives.
Company newsPFE
Explain this story: Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
Pfizer distributed $48.8 billion in dividends and buybacks over the last five years, yet its stock experienced a total return of -16.8% during the same period, significantly underperforming the S&P 500. This paradox highlights the challenge for mature, profitable companies to generate shareholder value when growth lags, emphasizing the importance of a strong R&D pipeline to sustain long-term growth and justify capital return policies. Investors are left questioning whether generous payouts compensate for a declining stock value without future growth drivers.
OtherTrefis
Company newsMRNA
Explain this story: Moderna, Inc. Stock Analysis: Momentum Builds Amid Overbought Signals
Moderna, Inc. (MRNA) stock surged nearly 7% to a 52-week high of $194.82, displaying a strong bullish trend above all major moving averages. However, technical indicators like the daily RSI14 at 75.12 and price trading above the upper Bollinger Band suggest the stock is overbought and may be due for a pause or consolidation. While the overall trend remains bullish, short-term momentum on hourly charts shows signs of cooling, warranting disciplined positioning.
OtherThe CryptonomistSector and industry: Healthcare
Company newsBIIB
Explain this story: Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast
Helus Pharma (operating as Cybin Inc.) CEO Michael Halstead will participate in a webcast fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company is advancing HLP003, a Phase 3 novel serotonergic agonist (NSA) with FDA Breakthrough Therapy Designation for major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder. This participation highlights the company's late-stage pipeline for mental health conditions.
OtherStock TitanHealthcare
Company newsAMGN
Explain this story: Kailera Therapeutics (Nasdaq:KLRA) - Stock Analysis
Kailera Therapeutics (KLRA) is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related conditions. The company recently reported positive Phase 3 data for its oral GLP-1 receptor agonist KAI-7535, showing significant weight loss and HbA1c reductions. KLRA is preparing for global Phase 3 trials for its Ribupatide candidates and has appointed a new CTO, indicating late-stage development and commercialization efforts, despite current unprofitability and a short cash runway.
OtherSimply Wall StreetHealthcare
Elsewhere
These links open other websites. We do not provide price data yet.